-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $28

Benzinga·11/21/2025 12:21:00
Listen to the news
Stifel analyst Paul Matteis initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $28.